Collectively, these findings not only shed light on an innovative regulatory mechanism governing MITF’s activity and its role in palbociclib resistance but also provide a potential therapeutic strategy for effectively managing palbociclib-resistant breast cancer patients. This evidence concerns the gene MITF and breast carcinoma.